Histological Findings in Antigen E Positive and Negative in Chronic Hepatitis B.

Mustafa Zanyar Akkuzu, Berat Ebik, Ferhat Bacaksiz, Ali Uzel, Ahmet Yavuz, Umit Karabulut
{"title":"Histological Findings in Antigen E Positive and Negative in Chronic Hepatitis B.","authors":"Mustafa Zanyar Akkuzu, Berat Ebik, Ferhat Bacaksiz, Ali Uzel, Ahmet Yavuz, Umit Karabulut","doi":"10.29271/jcpsp.2024.08.891","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the histopathological findings in patients with HBeAg-positive chronic HBV infection (immunotolerant phase in old terminology) and HBeAg-negative chronic HBV infection (inactive carrier phase in old terminology).</p><p><strong>Study design: </strong>Observational study. Place and Duration of the Study: Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkiye and Diyarbakir and Mersin University School of Medicine, Diyarbakir, Turkiye, from May 2014 to August 2022.</p><p><strong>Methodology: </strong>The difference between fibrosis and histological activity indices of 289 patients in the immunotolerant and inactive carrier phase who had liver biopsy was examined statistically. Additionally, the relationship of these data with age and gender was investigated.</p><p><strong>Results: </strong>While 236 (81.7%) of the patients were in the inactive carrier phase, 53 (18.3%) patients were in the immunotolerant phase. The mean fibrosis score of patients in the immunotolerant stage was 2.0 ± 1.2, while it was 2.0 ± 1.0 in inactive carriers (p = 0.753). The number of patients with a fibrosis score of two and above was 21 (39.6%) in immunotolerant patients and 52 (22.0%) in inactive carrier patients (p = 0.004). In patients under 30 years of age, the mean fibrosis score was 1.7 ± 1.0. It was 2.0 ± 1.1 in those over 30 years of age (p = 0.016).</p><p><strong>Conclusion: </strong>Biochemical parameters or viral load cannot clearly reflect cellular damage in the liver. In the future, HBV DNA positivity alone may be the only criterion for the treatment.</p><p><strong>Key words: </strong>Chronic viral hepatitis B, Fibrosis, Immune tolerance phase, Inactive carrier phase.</p>","PeriodicalId":94116,"journal":{"name":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29271/jcpsp.2024.08.891","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the histopathological findings in patients with HBeAg-positive chronic HBV infection (immunotolerant phase in old terminology) and HBeAg-negative chronic HBV infection (inactive carrier phase in old terminology).

Study design: Observational study. Place and Duration of the Study: Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkiye and Diyarbakir and Mersin University School of Medicine, Diyarbakir, Turkiye, from May 2014 to August 2022.

Methodology: The difference between fibrosis and histological activity indices of 289 patients in the immunotolerant and inactive carrier phase who had liver biopsy was examined statistically. Additionally, the relationship of these data with age and gender was investigated.

Results: While 236 (81.7%) of the patients were in the inactive carrier phase, 53 (18.3%) patients were in the immunotolerant phase. The mean fibrosis score of patients in the immunotolerant stage was 2.0 ± 1.2, while it was 2.0 ± 1.0 in inactive carriers (p = 0.753). The number of patients with a fibrosis score of two and above was 21 (39.6%) in immunotolerant patients and 52 (22.0%) in inactive carrier patients (p = 0.004). In patients under 30 years of age, the mean fibrosis score was 1.7 ± 1.0. It was 2.0 ± 1.1 in those over 30 years of age (p = 0.016).

Conclusion: Biochemical parameters or viral load cannot clearly reflect cellular damage in the liver. In the future, HBV DNA positivity alone may be the only criterion for the treatment.

Key words: Chronic viral hepatitis B, Fibrosis, Immune tolerance phase, Inactive carrier phase.

慢性乙型肝炎 E 抗原阳性和阴性患者的组织学检查结果
目的确定 HBeAg 阳性慢性 HBV 感染(旧称免疫耐受期)和 HBeAg 阴性慢性 HBV 感染(旧称非活动携带期)患者的组织病理学结果:研究设计:观察性研究。研究地点和时间:2014年5月至2022年8月,土耳其迪亚巴克尔,迪亚巴克尔加齐-亚萨吉尔教育和研究医院,迪亚巴克尔卫生科学大学,消化内科;土耳其迪亚巴克尔,迪亚巴克尔和梅尔辛大学医学院:对 289 名接受肝活检的免疫耐受期和非活动携带期患者的肝纤维化指数和组织学活动指数之间的差异进行统计分析。此外,还研究了这些数据与年龄和性别的关系:结果:236 名患者(81.7%)处于非活动携带期,53 名患者(18.3%)处于免疫耐受期。免疫耐受期患者的平均纤维化评分为(2.0 ± 1.2)分,而非活动携带者的平均纤维化评分为(2.0 ± 1.0)分(p = 0.753)。在免疫耐受期患者中,纤维化评分达到 2 分及以上的患者人数为 21 人(39.6%),非活动携带者患者为 52 人(22.0%)(p = 0.004)。在 30 岁以下的患者中,平均纤维化评分为 1.7 ± 1.0。结论:结论:生化指标或病毒载量不能明确反映肝脏的细胞损伤。结论:生化指标或病毒载量不能明确反映肝脏的细胞损伤,未来,HBV DNA 阳性可能是治疗的唯一标准:慢性乙型病毒性肝炎 纤维化 免疫耐受期 非活动载体期
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信